🧬 BIOTECH CATALYST AI SCANNER – January WK4

The biotech sector enters Q1 2026 with renewed optimism as XBI hovers around $120-131, digesting strong 2025 gains that saw the equal-weight ETF outperform the broader health sector. Dealmaking chatter continues to drive sentiment, with Mizuho analysts pointing to sustained M&A activity as big pharma fills pipelines through

🧬 BIOTECH CATALYST AI SCANNER – January WK3

Last week's 44th annual J.P. Morgan Healthcare Conference closed with a whimper rather than a bang. The industry's premier gathering—where mega-deals typically set the tone for the year—delivered what prominent biotech investor Brad Loncar called "the slowest JPM for news in a

🧬 BIOTECH CATALYST AI SCANNER – January WK2

Takeover Rumors Swirl Around Revolution Medicines and Abivax as Industry Giants Hunt for Blockbusters The 44th Annual J.P. Morgan Healthcare Conference officially begins today, January 12, 2026, setting the stage for what analysts are already calling a "banner year" for biopharma M&A. The dealmaking atmosphere

Alumis (ALMS) Spikes 40%: Why I Shorted the Overnight Gap Ahead of Data

And it wasn't a very good idea!

🧬 BIOTECH CATALYST AI SCANNER — January WK1

After a jam-packed December 2025, we enter the second week of 2026 with a sharply divided biotech market. While the XBI struggles to find its footing, our scanner has identified a distinct bifurcation: a cluster of “Pressure Cooker” setups—micro-caps with shrinking cash runways colliding with near-term data—versus well-capitalized

Season's Greetings from BioStockInfo.com

As we approach the end of the year, I want to take a moment to wish all our subscribers a very Merry Christmas and a Happy New Year. It has been a year of navigating the volatile biotech markets together, and I truly appreciate the community of independent-minded investors we&

🧬 BIOTECH CATALYST AI SCANNER — December WK3

The XBI sits at $123 near its 52-week high of $125.87—a 27% climb from April lows that's rewarded risk-takers but now leaves less margin for error. With year-end tax selling and portfolio rebalancing underway, the question isn't whether biotech is "back" but

The Weight Loss "World War" Expands: New Fronts Open in RNA and Oral Therapies

Two emerging biotechs just became the most attractive acquisition targets in obesity after releasing game-changing Phase 1 and Phase 2 data on December 8th.

🧬 BIOTECH CATALYST AI SCANNER — December WK2

Black Friday sale extended to biotechs, with numerous attractive companies trading at bargain prices. Outcome of last week's scanner revealed a significant surprise, especially with CAPR despite ongoing skepticism about the data’s credibility. JANX, as discussed in my recent article, disappointed investors. However, this is the nature

Weight Loss "World War II" : Beyond Ozempic and Mounjaro

The $1 trillion battleground where pharma giants and scrappy biotechs are fighting for supremacy — and why the real winners may be patients who couldn't afford these drugs before.

Janux Therapeutics ($JANX): The "Pluvicto Killer" Thesis Is Alive, But the Hype Had to Die First

In the high-stakes world of biotechnology, "good" is often not enough when the market is pricing in "perfection." Yesterday, Janux Therapeutics ($JANX) released updated Phase 1 data that triggered a sharp >40% sell-off. The market’s simplistic algorithm—"No massive beat on the headline

🧬 BIOTECH CATALYST AI SCANNER — December WK1

The XBI just logged a +10.72% gain over 21 days—and the beaten-down clinical-stage names are stirring. This week's scanner combed through 250+ catalyst events expected within 10-45 days. What jumps off the screen? Eight companies currently trade below their cash balances. The market has essentially written